Dr. Tripathy on the Development of Palbociclib in Breast Cancer

Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at baseline saw some increase in adherence.

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Lerociclib plus fulvestrant demonstrated a progression-free survival (PFS) advantage across all patient subgroups with HR–positive, HER2–negative advanced breast cancer.

After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.